“showed a trend”

The results showed a trend of lower incidence of GVHD in G-BM comparing to that in unstimulated BM group (II–IV aGVHD, 12.2% vs 26.78%, P = 0.070; overall cGVHD 22.3% vs 37.5%, P = 0.120, respectively).

In the FST (F2.45 = 3.242, p = 0.048, n = 16), CUS rats showed a trend toward more time spent immobile over the 6-min test period than rats of the non-CUS control group (p = 0.070).

A mixed model analysis combining the two time points (Table 4 ) found that only Eotaxin-3, TARC and PYY levels showed a trend (p = 0.07, p = 0.06 and p = 0.07, respectively).

Using Flk1 GFP/+ (WT-Flk1) [ 17 ] and CXCL12 Gagtm/Gagtm :Flk1 GFP/+ (KI-Flk1) mice, which have green fluorescent endothelial cells (ECs), cytometric analysis also showed a trend to an increase in the number of muscle ECs in the KI-Flk1 mice when compared to the WT-Flk1 mice ( p = 0.07; Additional file 2 : Figure S1E).

Serum corticosterone was not affected by OVX but OVX + E2 showed a trend toward a lower concentration relative to sham and OVX (p = 0.07).

In the multivariable analysis including all the clinical variables, “age” was again the only variable predictive of AF recurrence (HR 1.06; 95% CI 1.02, 1.11; p = 0.002), while SD-TPS only showed a trend towards higher AF recurrence risk (HR 1.04; 95% CI 1.00, 1.10; p = 0.07) (Fig. 3 ).

For households using unimproved water sources, Aquatabs use showed a trend toward improved FCR (aOR 0.12 [95%CI: 0.01, 1.19]; p = 0.070), though the association was not significant and should be interpreted with caution due to the low number of observations.

The animal analyses showed a trend in the reduction of BP with higher THC doses ( p = 0.07), with no change in HR.

Treatment also showed a trend towards a reduction in all-cause mortality( p =0.07).

Overall cardiovascular mortality Data from 11 studies showed a trend towards lower overall CV mortality in the IV iron group compared with the control group (OR = 0.88, 95% CI: 0.76 to 1.01, P = 0.07; Figure 4 ).

They also showed a trend toward recurrent infections, albeit not insignificant ( p = 0.07).

Remarkably, the high dose of 1.5 mg was ineffective, but the low dose of 0.5 mg showed a trend towards a 50–61% decrease in the number of new enhancing lesions as compared with placebo ( p = 0.07).

No significant interaction effects were observed, although the interaction between intervention and time showed a trend ( p = 0.07) ( Table 2 ).

Similarly, patients presenting the highest angiogenin levels presented a normal MRC score at 6 months ( p = 0.043; Figure 4D ) and functional outcomes assessed by the Rankin scale also showed a trend toward better improvement at 1 month ( p = 0.07; Figure 4E ), showing the association between high angiogenin levels and better neurological improvements.

Duffy-null patients showed a trend toward lower ANC at day 30 (0.9 vs 1.4; P = .07), with significantly lower values at 60 days (1.7 vs 2.6; P = .01) and 90 days (1.6 vs 2.3; P = .002; Figure 1 B) after CAR-T.

When examining subdimensions of FT, the burden of depleted FT coping resources (coping FT) was strongly associated with the risk of repeat AC visits (RR = 1.27, 95% CI 1.15–1.40, P < 0.001) while material FT burden showed a trend toward association (RR = 1.07, 95% CI 0.99–1.15, P = 0.07).

In our study, operation time showed a trend towards statistical significance in the incidence of post-CP infection ( p =0.07), explaining the higher infection rate associated with AB and PP compared with CT.

The rejection group showed a trend of higher body mass index (24.13±3.92 vs. 22.40±3.31 kg/m 2 , P=0.070) and lower tacrolimus levels than the no rejection group, although mycophenolate mofetil (MMF) doses were not lower in the rejection group.

The secondary endpoints, progression-free survival and AML-free survival were also investigated and showed a trend to a more favorable outcome for patients with elevated HbF: the median progression-free survival was 7.7 months versus 2.4 months (HR=0.32; 95% CI: 0.10–1.10; P =0.07) ( Figure 3B ) and the median AML-free survival was 13.1 months versus 7.6 months (HR=0.42; 95% CI: 0.13–1.38; P =0.15) ( Figure 3C ).

Patients with high Lu/BCAM expression showed a trend toward larger tumor size ( p = 0.07) and lower disease-specific survival ( p = 0.08), although not reaching statistical significance.

During the go/no-go task, there was a treatment × trial × group interaction, although this finding only showed a trend towards statistical significance ( F 26 = 3.38, P = 0.07).

QPCR showed a trend of reduced Slc46a1 transcript levels in KO compared to WT antNPCs that reached borderline significance ( P ≤ 0.07), supported by a Western blot analysis that revealed notable loss in PCFT protein expression in Tet1 KO cells (Fig. 6C,D ).

When comparing groups, the I allele showed a trend towards a reduced risk of BC (OR = 0.64, 95% CI 0.41–1.02, p = 0.07).

Cin30 administration showed a trend toward reversing the Lac1-induced effect ( p = 0.07; Figure 5 B).

Behaviorally, schizophrenia group showed a trend level of higher subjective amusement than healthy controls ( p < 0.07, Table 1 ).